COVID Risk in T1D; Lilly to Drop Some Insulin Prices; New ADA/EASD T1D Guideline

Adults over age 40 with type 1 diabetes (T1D) faced more severe COVID-19 outcomes, including a higher risk of hospitalization and death, compared with children and young adults with the condition. “These findings indicate the need for age-tailored treatments, immunization, and clinical management of individuals affected by type 1 diabetes and COVID-19,” said the study’s lead author, Carla Demeterco-Berggren, MD, PhD, of the University of California San Diego, in a statement. (The Journal of Clinical Endocrinology & Metabolism)

Vertice Pharma found that its treatment Thyquidity, an oral liquid solution of levothyroxine sodium, was bioequivalent to Synthroid tablets (600 mcg) in a small study.

Eli Lilly announced plans to slash the U.S. list price of its Insulin Lispro Injection by 40% starting on January 1, 2022 — dropping the list price to what it was in 2008. This price reduction will include non-branded insulins, including Insulin Lispro Injection, which is an alternative to Humalog U-100.

The American Diabetes Association and the European Association for the Study of Diabetes (EASD) released a joint consensus report outlining the best management strategies for adult patients with T1D. “This new consensus statement not only brings in the advances that have been made in treating type 1 diabetes in recent years, but also covers other vital areas from a patient perspective — such as the psychosocial consequences of living with the condition, that can sometimes be neglected,” said one of the authors, Anne Peters, MD, of the University of Southern California in Los Angeles, in a statement. (Diabetes Care)

And catch up on MedPage Today‘s coverage of EASD’s annual meeting here.

The Mayo Clinic in Rochester, Minnesota, topped Newsweek‘s list of 2022 World’s Best Specialized Hospitals for endocrinology. The number two and number three spots went to Massachusetts General Hospital and Cleveland Clinic, respectively.

According to pooled data from the STEP (Semaglutide Treatment Effect in People With Obesity) trials, gastrointestinal events were quite common with semaglutide — most frequently nausea (43.9% vs 16.1% of patients on placebo), diarrhea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%) and constipation (24.2% vs 11.1%). However, semaglutide-induced weight loss was largely independent of gastrointestinal side effects. (Diabetes, Obesity and Metabolism)

The Transatlantic Alliance Award, a joint honor bestowed by the Endocrine Society and the European Society of Endocrinology, was given to Shlomo Melmed, MB, ChB, of Cedars-Sinai in Los Angeles, for his “pioneering research” in pituitary medicine and endocrine tumors.

Amolyt Pharma announced positive phase I trial data of its investigational hypoparathyroidism treatment AZP-3601, at the American Society for Bone and Mineral Research 2021 Annual Meeting. Catch up on our coverage from the meeting here.